Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 13;35(43):5872-5877.
doi: 10.1016/j.vaccine.2017.08.086. Epub 2017 Sep 6.

Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink

Elizabeth R Vickers  1 , David L McClure  2 , Allison L Naleway  3 , Steven J Jacobsen  4 , Nicola P Klein  5 , Jason M Glanz  6 , Eric S Weintraub  7 , Edward A Belongia  8
Affiliations

Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink

Elizabeth R Vickers et al. Vaccine. .

Abstract

Background: Influenza-like illness and inflammation are known risk factors for venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). However, few studies have characterized the risk of VTE following influenza vaccination. We examined VTE risk after vaccination in adults 50years old and older within the Vaccine Safety Datalink (VSD).

Methods: We used the self-controlled case series method to determine the risk of VTE among age-eligible adults who received influenza vaccine (with or without pandemic H1N1) and experienced a VTE during the months of September through December in 2007 through 2012. Presumptive VTE cases were identified among VSD participants using diagnostic codes, diagnostic tests, and oral anticoagulant prescription. Potential cases were validated by medical record review. The VTE incidence rate ratio was calculated among confirmed cases for the risk window 1 to 10days after vaccination relative to all other person-time from September through December.

Results: Of the 1,488 presumptive cases identified, 508 were reviewed, of which 492 (97%) were confirmed cases of VTE. The analysis included 396 incident, confirmed cases. Overall, there was no increased risk of VTE in the 1 to 10days after influenza vaccination (IRR=0.89, 95% CI 0.69-1.17) compared to the control period. Results were similar when all person-time was censored before vaccination. A post hoc analysis showed an increased risk among current tobacco smokers (IRR=2.57, 95% CI 1.06-6.23). No clustering of VTE was observed in the 1-42days after vaccination.

Discussion: Overall, there was no evidence that inactivated influenza vaccine was associated with VTE in adults ≥50years old. An increased risk was found among current smokers in a post hoc analysis. These findings are consistent with previous research and support the safety of annual vaccination in this population.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

ALN receives research support from Pfizer, Merck, and MedImmune (now AstraZeneca) for unrelated studies. NPK receives research support from GlaxoSmithKline, Sanofi Pasteur, Protein Science, Pfizer, Merck, and MedImmune (now AstraZeneca) for unrelated studies. The remaining authors report no conflicts of interest.

Figures

Fig. 1.
Fig. 1.
Self-controlled case series design for determining the risk of venous thromboembolism (VTE) following influenza vaccination.
Fig. 2.
Fig. 2.
Identification of chart-confirmed, incident cases of venous thromboembolism (VTE).
Fig. 3.
Fig. 3.
Month of venous thromboembolism (VTE) onset and month of influenza vaccination among adults ≥50years old, 2007–2012.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology. Am J Med 2004. July;1(117):19–25. 10.1016/j.amjmed.2004.01.018. - DOI - PubMed
    1. Fowkes FJ, Price JF, Fowkes FG. Incidence of diagnosed deep vein thrombosis in the general population: systematic review. Eur J Vasc Endovasc Surg 2003. January;25:1–5. 10.1053/ejvs.2002.1778. - DOI - PubMed
    1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012. May 12;379(9828):1835–46. 10.1016/S0140-6736(11)61904-1. - DOI - PubMed
    1. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol 2012. September;25(3):235–42. 10.1016/j.beha.2012.06.007. - DOI - PubMed
    1. Clayton TC, Gaskin M, Meade TW. Recent respiratory infection and risk of venous thromboembolism: case-control study through a general practice database. Int J Epidemiol 2011. June;40(3):819–27. 10.1093/ije/dyr012. - DOI - PMC - PubMed

Publication types

Substances